Timberlyne Therapeutics

Keymed-anchored NewCo taking the anti-CD38 antibody CM313 into autoimmune disease outside China.

1. Core Product / Service

Timberlyne (San Diego) launched in January 2025 with exclusive worldwide rights, excluding Greater China, to CM313, an IgG1 anti-CD38 monoclonal antibody discovered by Chengdu-based Keymed Biosciences [1][2]. CD38 is highly expressed on plasma cells and plasmablasts, so CM313 is positioned for antibody-driven autoimmune disorders rather than only myeloma (where daratumumab and isatuximab are established).

CM313 has been studied in relapsed/refractory multiple myeloma, systemic lupus erythematosus and immune thrombocytopenia (ITP); a New England Journal of Medicine study reported a 95% response rate in treatment-refractory ITP [2]. Keymed's China programme has since expanded to subcutaneous CM313 in ITP, SLE, IgA nephropathy, aplastic anaemia and platelet-transfusion refractoriness [5].

2. Target Users & Pain Points

• Patients: refractory antibody-mediated autoimmune diseases (ITP, SLE, nephropathies) where B-cell-directed drugs such as anti-CD20 miss long-lived plasma cells.
• Licensor: Keymed gains a Western development vehicle while remaining the largest shareholder.

3. Competitive Landscape

4. Unique Observations

• All clinical evidence still sits in China. A ClinicalTrials.gov search for CM313 returns 14 studies, every one sponsored by Keymed or Chinese hospitals; none lists Timberlyne as sponsor as of October 2026 [5]. Discovery, CMC and the human data package come from Keymed, while the NewCo's job is to design and fund ex-China registration trials — the standard NewCo division of labour [3].
• Licensor as controlling-scale shareholder. Keymed holds 25.79% after the Series A, making it Timberlyne's largest shareholder — a higher stake than Hengrui's 19.9% in kailera-therapeutics [3].
• Keymed runs repeated NewCos. It previously spun CM512 and CM536 into Belenos Biosciences (July 2024, ~30% stake), so Timberlyne is part of a deliberate strategy rather than a one-off [3].

5. Financials / Funding

• Series A: $180M (January 2025), led by Abingworth, Bain Capital Life Sciences and Venrock Healthcare Capital Partners; Boyu Capital, Lilly Asia Ventures, Braidwell and 3H Health Investment participated [2].
• Keymed terms: launch coverage described an "undisclosed" upfront plus milestones, royalties and equity [2]; Keymed later reported $30M in upfront and near-term payments and 25.79% ownership [3][4].
• No later financing, trial start or exit has been publicly reported as of October 2026.

6. People & Relationships

• Creator: Mountainfield Venture Partners, a biopharma company-creation firm, formed Timberlyne with Keymed [2].
• CEO: Daniel Curran, M.D., per January 2025 launch coverage [6].
• Licensor / largest shareholder: Keymed Biosciences.
• Investors: Abingworth, Bain Capital Life Sciences, Venrock HCP, Boyu, LAV, Braidwell, 3H [2].
• Peer NewCos: kailera-therapeutics, braveheart-bio, candid-therapeutics, verdiva-bio, windward-bio, sentivera.

Sources

• [1] Fierce Biotech, "Biotech creator and China's Keymed launch company with $180M Series A for CD38-targeting antibody" (accessed 2026-10-14)
• [2] Pulse 2.0, Timberlyne $180M Series A, 2025-01-13 (accessed 2026-10-14)
• [3] Research notes on China-asset NewCos, 2026-10-14 (citing Keymed disclosures and Clifford Chance)
• [4] Keymed Biosciences, 2025 annual results and business update (accessed 2026-10-14); Clifford Chance, "Clifford Chance advises Keymed on out-licensing transaction" (accessed 2026-10-14)
• [5] ClinicalTrials.gov API search for CM313 (accessed 2026-10-14)
• [6] Inside Precision Medicine, Timberlyne launch coverage (accessed 2026-10-14)